Biofilm Formation and Its Association with Antimicrobial Resistance among Clinical Isolates of *Acinetobacter baumannii* at a Tertiary Care Hospital in Dhaka City of Bangladesh

Sharmeen Sultana¹, SM Shamsuzzaman², Md. Abdullah Yusuf³, M Asifudduza⁴, Tania Rahman⁵, Momtaz Begum⁶, Tarana Jahan⁷

¹Assistant Professor, Department of Microbiology, Monno Medical College, Manikganj, Bangladesh; ²Professor & Head, Department of Microbiology, Dhaka Medical College, Dhaka, Bangladesh; ³Associate Professor, Department of Microbiology, National Institute of Neurosciences & Hospital, Dhaka, Bangladesh; ⁴Phase-B, Resident (MD-Cardiology), National Heart Foundation Hospital & Research Institute, Dhaka, Bangladesh; ⁵Assistant Professor, Department of Microbiology, Khwaja Yunus Ali Medical College, Sirajganj, Bangladesh; ⁶Assistant Professor, Department of Microbiology, Dhaka Community Medical College, Dhaka, Bangladesh; ⁷Assistant Professor, Department of Microbiology, Monno Medical College, Manikganj, Bangladesh

[Received: 12 September 2021; Accepted: 3 November 2021; Published: 1 December 2021]

**Abstract**

**Background:** *Acinetobacter baumannii* is responsible for nosocomial infections which are related to the biofilm forming capacity of this pathogen. **Objective:** The purpose of the present study was to detect biofilm formation in clinical isolates of *Acinetobacter baumannii* and to observe relationship between biofilm formations with its antimicrobial resistance. **Methodology:** This cross-sectional study was conducted in the Department of Microbiology of Dhaka Medical College and Hospital, Dhaka, Bangladesh from July 2015 to June 2016. *Acinetobacter baumannii* was isolated from different specimens and was identified and were screened for biofilm production by tissue culture plate method. Antimicrobial susceptibility test was done by disc diffusion method. **Results:** A total 300 samples were studied of which 26(8.7%) were *Acinetobacter baumannii*. From 26 isolated *Acinetobacter baumannii*, 16(61.5%) were biofilm producers. Biofilm producing *Acinetobacter baumannii* were 100% resistant to ceftriaxone, ceftazidime, amoxiclav, amikacin and ciprofloxacin. Resistance to imipenem, meropenem, cephotaxime, cefepime and gentamicin were also higher among biofilm producing *Acinetobacter baumannii* isolates than non-biofilm producers. **Conclusions:** In conclusion the ability of *Acinetobacter baumannii* forms biofilm and biofilm production has strong association with antimicrobial resistance. [Bangladesh Journal of Infectious Diseases, December 2021;8(2):82-86]

**Keywords:** *Acinetobacter baumannii*; biofilm; tissue culture plate method; antimicrobial resistance

**Correspondence:** Dr. Sharmeen Sultana, Assistant Professor, Department of Microbiology, Monno Medical College, Monno City, Gilondo, Manikganj, Bangladesh; Email: nila21786@gmail.com; Cell no.: +8801724819455; ORCID ID: https://orcid.org/0000-0002-0503-0693

**Conflict of interest:** The author(s) declared no potential conflicts of interest.

**Funding agency:** No

**Contribution to authors:** All authors were involved from protocol preparation to manuscript writing.

**How to cite this article:** Sultana S, Shamsuzzaman SM, Yusuf MA, Asifudduza M, Rahman T, Begum M, Jahan T. Biofilm Formation and Its Association with Antimicrobial Resistance among Clinical Isolates of *Acinetobacter baumannii* at a Tertiary Care Hospital in Dhaka City of Bangladesh. Bangladesh J Infect Dis 2021;8(2):82-86

**Copyright:** ©2021. Sultana et al. Published by Bangladesh Journal of Infectious Diseases, This article is published under the Creative Commons CC BY-NC License (https://creativecommons.org/licenses/by-nc/4.0/). This license permits use, distribution and reproduction in any medium, provided the original work is properly cited, and is not used for commercial purposes.
Biofilm Formation of Acinetobacter baumannii

Sultana et al

Introduction

Multidrug resistant *Acinetobacter baumannii* is a rapidly emerging opportunistic pathogen associated with a variety of nosocomial infection, including ventilator-associated pneumonia, bacteremia, surgical site infections, secondary meningitis and urinary tract infections. Artificial ventilation and other invasive procedures, exposure to antibiotics, colonization pressure, environmental contamination in ICU and underlying illness facilitate the spread of these multidrug-resistant species in ICU. *Acinetobacter baumannii* is the most common cause of device-related nosocomial infection. Biofilm formation is thought to be a key pathogenic feature, especially in relation to intravascular line infections and ventilator associated pneumonia.

Biofilm is defined as a structured community of bacterial cells enclosed in a self-produced polymeric matrix and adherent to an inert or living surface. Generally, two properties are often associated with biofilm producing bacteria, namely, the increased synthesis of exopolysaccharide (EPS) and the development of antibiotic resistance. Mechanisms responsible for antimicrobial resistance in organisms producing biofilms may be delayed penetration of the antimicrobial agents through the biofilm matrix, altered growth rate of biofilm organisms and other physiological changes due to the biofilm mode of growth. The ability of bacterial cells to transfer genes horizontally is enhanced within biofilm communities, thereby facilitating the spread of antibiotic resistance.

Infections due to *Acinetobacter baumannii* is difficult to eradicate as *Acinetobacter baumaninni* growing in biofilm are resistant to most of the antimicrobials thereby limiting therapeutic options. Biofilm formation on surfaces and expression of multidrug resistance favours dissemination of *Acinetobacter baumannii* in hospital setting. Therefore, the present study was undertaken on clinical isolates of *Acinetobacter baumannii* to determine biofilm formation and to observe relationship between biofilm formation and antimicrobial resistance among *Acinetobacter baumannii* isolates.

Methodology

This cross-sectional study was carried out at Department of Microbiology in Dhaka Medical College (DMC), Dhaka, Bangladesh over a period of one year which was from July 2015 to June 2016. Tracheal aspirate, blood, urine and wound swab samples were collected from all recruited patients for microscopy, culture and sensitivity testing. Samples were collected from patients of all age groups, both sexes, who were critically ill and suspected for pneumonia, urinary tract infection, septicemia, skin and soft tissue infection. Samples were inoculated on Blood Agar and MacConkey Agar plates under strict aseptic conditions. Plates were incubated at 37°C for 24 to 48 hours. *Acinetobacter baumannii* was identified and confirmed by Gram staining as Gram negative coccobacilli or cocci in pairs, non-motile, oxidase negative, Alkaline/Alkaline (K/K) reaction in Triple Sugar Iron (TSI) slant, catalase positive, Indole negative, Citrate utilization test positive, urease test negative. It showed Oxidative-Fermentative (O/F) test –oxidative. Susceptibility to antimicrobial agents of all isolates was done by Kirby Bauer modified disc diffusion technique using Mueller Hinton agar plates and zones of inhibition were interpreted according to CLSI guidelines (2015). Biofilm formation was determined by Tissue Culture Plate (TCP) method. Organisms isolated from fresh agar plates were inoculated in 10 ml of brain heart infusion broth with 1.0% glucose. Broths were incubated at 37°C for 24 hours. Then the cultures were diluted 1:100 with fresh broth. Individual wells of sterile 96 wells flat bottom polystyrene tissue culture plates were filled with 200 µl of the diluted cultures. The control organisms were treated the same way as the test organisms also incubated, diluted and added to tissue culture plates. Negative control wells contained inoculated sterile broth. The plates were incubated at 37°C for 24 hours. After incubation, the contents of each well were removed by gentle tapping. The wells were washed with 0.2 ml of phosphate buffer saline (PH 7.2) four times. The adhered biofilm formed by bacteria was fixed by 2% sodium acetate and stained by crystal violet (0.1%). Excess stain was removed with distilled water and plates were kept for drying. The optical density (OD) of stained adherent biofilm was obtained by using micro ELISA autoreader at wavelength of 570 nm. The experiment was performed in triplicate and repeated three times. The interpretation of biofilm production was done according to the criteria of Stepanovic et al (2015) (Table 1). The average OD values were calculated for all tested strains and negative controls, since all tests were performed in triplicate and repeated three times. Second, the cut off value (ODc) was established. It was defined as three standard deviate (SD) above the mean OD of the negative control: 

\[
\text{ODc} = \text{average OD of negative controls} + (3 \times \text{SD of negative control})
\]

In the present study, only strongly and moderately adherent isolates were...
considered as positive for biofilm formation while weakly adherent ones as negative for biofilm production.

Table 1: Interpretation of biofilm production

| Average OD value | Adherence | Biofilm production |
|------------------|-----------|--------------------|
| OD ≤ ODc         | None      | None               |
| ODc < OD ≤ 2ODc  | Weak      | Weak               |
| 2ODc < OD ≤ 4ODc | Moderate  | Moderate           |
| 4ODc < OD        | Strong    | High               |

Results

Total 300 samples were studied. Of which 130 were wound swabs, 80 were urine, 50 were endotracheal aspirates and 40 were blood samples. From 300 samples, 26 (8.7%) were Acinetobacter baumannii. Maximum number of Acinetobacter baumannii were isolated from endotracheal aspirate (38.0%) followed by (5.0%) from blood, (3.1%) from wound swab and (1.3%) from urine samples (Table 2). On testing by tissue culture plate method, from 26 isolated Acinetobacter baumannii, 16 (61.5%) were biofilm producers. The rate of biofilm production by isolated Acinetobacter baumannii from different clinical samples is recorded (Table 2).

Table 2: Biofilm production of isolated Acinetobacter baumannii from different clinical samples

| Type of Specimens | Positive for Acinetobacter baumannii | Positive for production of biofilm |
|-------------------|--------------------------------------|-----------------------------------|
| Wound swab        | 4 (3.1%)                             | 1 (25.0%)                        |
| Urine             | 1 (1.3%)                             | 1 (100.0%)                       |
| Endotracheal aspirate | 19 (38.0%)                        | 13 (68.4%)                       |
| Blood             | 2 (5.0%)                             | 1 (50.0%)                        |
| Total             | 26 (8.7%)                            | 16 (61.5%)                       |

For antibiotic resistance pattern among both positive and negative biofilm producing Acinetobacter baumannii isolates, higher antibiotic resistance pattern was observed among biofilm producers Acinetobacter baumannii isolates compared to the non-biofilm producers’ isolates. 100% resistance pattern was observed among biofilm producing Acinetobacter baumannii isolates for ceftriaxone, ceftazidime, amoxiclav, amikacin and ciprofloxacin, compared to 80%, 80%, 80%, 60% and 60% resistance pattern for the same antibiotics among the non-biofilm producing Acinetobacter baumannii isolates. Higher level of resistance for other antibiotics was also recorded (Table 3).

Table 3: Antibiotic Resistance Pattern of Biofilm and Non-Biofilm Producers of Acinetobacter baumannii Isolates

| Antimicrobial agent          | Biofilm positive resistant isolates (n=16) | Biofilm negative resistant isolates (n=10) | Resistance of all isolates (n=26) |
|------------------------------|-------------------------------------------|------------------------------------------|----------------------------------|
| Imipenem                     | 15 (93.8%)                                | 6 (60.0%)                                | 21 (80.8%)                       |
| Meropenem                    | 15 (93.8%)                                | 6 (60.0%)                                | 21 (80.8%)                       |
| Ceftriaxone                  | 16 (100.0%)                               | 8 (80.0%)                                | 24 (92.3%)                       |
| Ceftazidine                  | 16 (100.0%)                               | 8 (80.0%)                                | 24 (92.3%)                       |
| Cefotaxime                   | 15 (93.8%)                                | 9 (90.0%)                                | 24 (92.3%)                       |
| Cefepime                     | 15 (93.8%)                                | 9 (90.0%)                                | 24 (92.3%)                       |
| Amoxiclav                    | 16 (100.0%)                               | 8 (80.0%)                                | 24 (92.3%)                       |
| Amikacin                     | 16 (100.0%)                               | 6 (60.0%)                                | 22 (84.6%)                       |
| Gentamicin                   | 15 (93.8%)                                | 7 (70.0%)                                | 22 (84.6%)                       |
| Ciprofloxacin                | 16 (100.0%)                               | 6 (60.0%)                                | 22 (84.6%)                       |
| Piperacillin-Tazobactam      | 14 (87.5%)                                | 9 (90.0%)                                | 23 (88.5%)                       |
| Colistin                     | 2 (12.5%)                                 | 1 (10.0%)                                | 3 (11.5%)                        |
| Tigecycline                  | 4 (25.0%)                                 | 2 (20.0%)                                | 6 (23.1%)                        |

Discussion

Acinetobacter baumannii infections present a global medical challenge. They are opportunistic pathogens and are particularly successful at colonizing and persisting in the hospital environment. They are able to resist desiccation and survive on inanimate surfaces for years. Interest in this organism has been growing rapidly because of the emergence of multi-drug-resistant strains,
some of which are pan-resistant to antimicrobial agents. It is also among the most common causes of device-related nosocomial infection that results when the organism is able to resist physical and chemical disinfection, often by forming a biofilm. Biofilm exhibit resistance to antibiotics by various methods like restricted penetration of antibiotic into biofilms, decreased growth rate and expression of resistance genes.

In the current study, maximum number of Acinetobacter baumannii have been isolated from endotracheal aspirate (38.0%) followed by (5.0%) from blood, (3.1%) from wound swab and (1.3%) from urine samples. In India, a study reported that, the high isolation rate of Acinetobacter baumannii of about 42% were from tracheal aspirates, 29.0% from sputum, 16.0% from pus, 6.0% from blood and other body fluids, 4% from urine and 3.0% from bronchoalveolar lavage.

In the present study, 61.5% isolates are biofilm producers by tissue culture plate method. This is in concordance with the study of Rao et al in which 62.0% isolates of Acinetobacter are biofilm producers. This study is also comparable with the other study in which 63.0% isolates are biofilm producers.

In this study, Acinetobacter baumannii showed 100% biofilm formation in urine, 68.4% in tracheal aspirate, 50.0% in blood and 25.0% in wound swab. Another study found that, biofilm formation by Acinetobacter baumannii were 76.4% in tracheal aspirate, 80.0% in wound swab, 75.0% in blood, 50.0% in sputum, 50.0% in pleural fluid, 75.0% in urine, 80.0% in cerebrospinal fluid.

This study shows association of biofilm formation with antibiogram of Acinetobacter baumannii isolates. Biofilm forming Acinetobacter baumannii isolates from different clinical sources are 100% resistant to ceftazidime, cefepime, amoxiclav, amikacin and ciprofloxacin. Nahar et al has also reported 100% resistance to amoxicillin, ceftriaxone, cefazidime, cefuroxime, and aztreonam in biofilm forming Acinetobacter species. In this study, higher level of resistance also seen in imipenem, meropenem, cefotaxime, cefepime, gentamycin and piperacillin-tazobactum. Resistance to most of the antibiotics is becoming common, and very few therapeutic options remain.

A study from India showed biofilm producers of Acinetobacter isolates were 100% resistant to imipenem, amikacin (82.0%), cefotaxime (88.0%), ciprofloxacin (70.0%) and aztreonam (38.0%)4. Study in South India showed, biofilm positive Acinetobacter showed resistance to ceftazidime (95.0%), cefepime (95.0%), aztreonam (85.0%), ciprofloxacin (85.0%), amikacin (80%), gentamycin (70.0%), imipenem (65.0%), pipercillin-tazobactum (40.0%) and netilmicin (20.0%)25.

Conclusion

In conclusion, the data obtained in the present work showed that most of the clinical isolates of Acinetobacter baumannii are biofilm producers especially from device in ICU samples and they are multidrug resistant. All biofilm producing Acinetobacter baumannii are resistant to clinically achievable levels of most commonly used antibiotics such as penicillin, cephalosporin, aminoglycosides, quinolone, carbapenem and monobactam group of drugs. Colistin and tigecycline remain the only agent that may be consistently active in vitro against Acinetobacter baumannii. However, colistin and tigecycline resistant Acinetobacter baumannii isolates are slowly emerging. This is very alarming for us that biofilm forming multidrug resistant Acinetobacter baumannii represents a severe threat in the treatment of hospitalized patients. Combination therapy can be an effective option. So a greater understanding of the antibiogram of Acinetobacter baumannii will help in development of effective treatment.

References

1. Fontana C, Favaro M, Minelli S, Boss MC, Testore GP, Leonardis F, Natoli S, Favalli C. Acinetobacter baumannii in intensive care unit: a novel system to study clonal relationship among the isolates. BMC Infect Dis 2008; 8: 79
2. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-582
3. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42: 692-699
4. Rao RS, Karthika RU, Singh SP, Shashikala P, Kanungo R, Jayachandran S, Prashanth K. Correlation between biofilm formation and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumannii. Indian Journal of Medical Microbiology 2008; 26 (4): 333-7.
5. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science 1999; 284: 1318-22
6. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother 2001; 45: 999-1007
7. Donlan RM, Costerton JW. Biofilms: the survival mechanisms of the clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-193
8. Bala M, Gupte S, Aggarwal P, Kaur M, Manhas A. Biofilm producing multidrug resistant Acinetobacter species from a tertiary care hospital: a therapeutic challenge. Int J Res Med Sci 2016; 4 (7): 3024-3026
Biofilm Formation of Acinetobacter baumannii

9. Collee JG, Marr W. Specimen collection, culture containers and media. In: Collee JG, Fraser AG, Marmion BP, Simmons A, eds. Mike & McCartney Practical Medical Microbiology, 14th ed. USA: Churchill Livingstone 1996: pp. 95-111
10. Cheesbrough M. Microbiological test. In: Cheesbrough M, (editor). District laboratory practice in tropical countries, Cambridge University press, UK. 2000: pp. 178-195
11. Constantinu S, Romanie A, Lancu LS, Filimon R, Tarasi I. Cultural and biochemical characteristics of Acinetobacter spp. strains isolated from hospital units. Journal of Preventive Medicine 2004; 12 (3-4): 35-42
12. Clinical and Laboratory Standard Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Twenty-fifth Informational Supplement. CLSI document M100-S25. Wayne, PA: CLSI; 2015
13. Christensen GD, Simpson WA, Younger JA, Baddour LM, Barrett FF, Melton DM, et al. Adherence of coagulase negative Staphylococci to plastic tissue cultures: a quantitative model for the adherence of Staphylococci to medical device. J Clin Microbiol 1985; 22 (6): 996-1006
14. Mathur T, Singhal S, Khan S, Upadhyay D J, Fatma T and Rattan A. Detection of biofilm formation among the clinical isolates of Staphylococci: An evaluation of three different screening methods. Indian Journal of Medical Microbiology 2006; 24: 25-9
15. Stepovovicic S, Vukovic D, Hola V, Di Bonaventura G, Djuvic S, Cirkvic I, Ruzicka I. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by Staphylococci. APMIS 2007; 115 (8): 891-9
16. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: Multidrug resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5: 939-51
17. Prashanth K, Badrinath S. Epidemiological investigation of nosocomial Acinetobacter infections using AP-PCR and Pulse field gel electrophoresis. Indian J Med Res 2005;122:408-18
18. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: An emerging challenge to clinicians. Ann Pharmacother 2004; 38: 1449-59.
19. Navon-Venezia S, Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005; 18: 306-13.
20. Prashanth K, Badrinath S. In vitro susceptibility pattern of clinically significant Acinetobacter species to commonly used cephalosporins, quinolones, and aminoglycosides. Indian J Med Microbiol 2004;22:97-103.
21. Kim L. Riddle of biofilm resistance. Antimic Ag Chemother 2001; 45 (4): 999-1007.
22. Rodriguez BJ, Marti S, Soto S, Fernandez CF, Cisneros JM, Pachon J, et al. biofilm formation in Acinetobacter baumannii: associated features and clinical implications. Clin Microbiol Infect 2008; 14: 276-8
23. Cevahir N, Demir M, Kaleli I, Gurbuz M, Tikvesli S. Evaluation of Biofilm production, gelatinase activity and mannose- resistant hemagglutination in Acinetobacter baumannii strains. J Microbiology, Immunology and Infection 2008; 41: 513-518.
24. Nahar A, Anwar S, Miah MRA. Association of biofilm formation with antimicrobial resistance among the Acinetobacter species in a tertiary care hospital in Bangladesh. J Med, 2013; 14 (1): 28-32.
25. Dheepa M, Vinitha L, Appalaraju B. Comparison of biofilm production and multiple drug resistance in clinical isolates of Acinetobacter baumannii from a tertiary care hospital in South India. Int J Pharm Biomed Sci 2011; 2(4), 103-107